X
NBIX icon

Xponance’s Neurocrine Biosciences NBIX Stock Holding History

Xponance’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62M Sell
27,419
-260
-0.9% -$38.6K 0.03% 403
2026
Q1 		$3.65M Buy
27,679
+2,669
+11% +$354K 0.03% 422
2025
Q4 		$3.55M Sell
25,010
-1,378
-5% -$200K 0.03% 411
2025
Q3 		$3.7M Buy
26,388
+413
+2% +$56K 0.03% 397
2025
Q2 		$3.26M Sell
25,975
-1,307
-5% -$150K 0.03% 430
2025
Q1 		$3.02M Buy
27,282
+215
+0.8% +$27.2K 0.03% 422
2024
Q4 		$3.69M Buy
27,067
+1,941
+8% +$240K 0.03% 383
2024
Q3 		$2.9M Sell
25,126
-102
-0.4% -$14K 0.03% 435
2024
Q2 		$3.47M Sell
25,228
-436
-2% -$59.8K 0.04% 376
2024
Q1 		$3.54M Buy
25,664
+4,216
+20% +$576K 0.04% 370
2023
Q4 		$2.83M Sell
21,448
-936
-4% -$108K 0.03% 386
2023
Q3 		$2.52M Sell
22,384
-55
-0.2% -$5.79K 0.03% 396
2023
Q2 		$2.12M Sell
22,439
-279
-1% -$27.3K 0.03% 458
2023
Q1 		$2.3M Buy
22,718
+386
+2% +$40.2K 0.03% 427
2022
Q4 		$2.67M Buy
22,332
+1,410
+7% +$165K 0.04% 376
2022
Q3 		$2.22M Buy
20,922
+57
+0.3% +$5.78K 0.04% 367
2022
Q2 		$2.03M Buy
20,865
+537
+3% +$49.6K 0.04% 369
2022
Q1 		$1.91M Sell
20,328
-92
-0.5% -$7.8K 0.03% 385
2021
Q4 		$1.74M Sell
20,420
-36
-0.2% -$3.31K 0.03% 420
2021
Q3 		$1.96M Sell
20,456
-159
-0.8% -$15K 0.04% 353
2021
Q2 		$2.01M Buy
20,615
+1,146
+6% +$110K 0.04% 372
2021
Q1 		$1.89M Buy
19,469
+9,938
+104% +$1.04M 0.04% 325
2020
Q4 		$914K Sell
9,531
-96
-1% -$9.27K 0.02% 489
2020
Q3 		$926K Buy
9,627
+94
+1% +$10.9K 0.02% 437
2020
Q2 		$1.16M Buy
+9,533
New +$1.05M 0.03% 356

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Xponance's NBIX Position: Q2 2026 in Review

Xponance reduced its Neurocrine Biosciences (NBIX) stake by 0.94% in Q2 2026, selling an estimated $38.6K and leaving 27,419 shares worth $4.62M. The position accounts for 0.03% of the portfolio, ranked #403.

Xponance first reported a position in NBIX in Q2 2020 and has held it in 25 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Xponance held 27,419 shares of Neurocrine Biosciences worth $4.62M as of Q2 2026.
  • Xponance sold 260 Neurocrine Biosciences shares in Q2 2026, an estimated $38.6K.
  • Neurocrine Biosciences made up 0.03% of Xponance's portfolio in Q2 2026, its #403 holding.
  • Xponance first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 25 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.